Condition: Gastric Cancer · HER2-positive Gastric Cancer · Sponsor: Gruppo Oncologico del Nord-Ovest
TRINITY is designed as a multicentre, randomized, open-label, interventional phase II study aimed at investigating the activity, efficacy and safety of trastuzumab-deruxtecan (T-DXd) plus capecitabine/5-fluorouracil as a post-operative treatment in localized/locally advanced gastric or gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma patients with HER2 overexpression/amplification and positive post-operative ctDNA after pre-operative 5-fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) regimen followed by radical surgery.
This description comes directly from the study's public registry record.
Filippo Pietrantonio, MD · +39 0223903807 · filippo.pietrantonio@istitutotumori.mi.it
Federica Palermo · +39 0223903835 · federica.palermo@istitutotumori.mi.it
Always discuss trial participation with your own doctor first.
| Fondazione IRCCS Istituto Nazionale dei Tumori di Milano | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06253650